Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Intratympanic HY01 in Sudden Sensorineural Hearing Loss
NCT04961099Phase 1Unknown
- Start
- Jun 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HY01 in sudden sensorineural hearing loss (SSHL) (2 arms). Primary endpoint: Safety of HY01 at 30 days. Status: unknown.
02
Drugs
HY01
03
Conditions
sudden sensorineural hearing loss (SSHL)
Beyond the preview
Go deeper on NCT04961099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04961099.